A Phase I/II Clinical Trial of Nivolumab and Plinabulin for Patients With Advanced Stage Non-small Cell Lung Cancer That Have Progressed Through First Line Platinum Doublet Chemotherapy
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Nivolumab (Primary) ; Plinabulin (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Nov 2017 According to a BeyondSpring Pharmaceuticals media release, phase 1 data on the safety and mechanism of action of this regimen are expected in the first quarter of 2018, Enrollement in the phase 2 portion has recently commenced.
- 29 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 31 Mar 2018.
- 21 Aug 2017 BeyondSpring anticipates initial safety data from this trial to be available in the second half of 2017, according to a company media release.